Sun Pharma’s European partner withdraws application for skin cancer treatment therapy

India’s largest drugmaker, Sun Pharmaceutical Industries Ltd., announced on Wednesday that its European biotech partner Philogen has voluntarily withdrawn the marketing authorisation application (MAA) for its investigational therapy Nidlegy from…

  • Pharma
  • October 17, 2023
  • 205 views
Skin cancer drug Nidlegy shows positive results in Phase III trial

Italian-Swiss biotechnology company Philogen and Sun Pharmaceutical announced positive results from the Phase III “Pivotal” trial of Nidlegy on locally advanced melanoma. Nidlegy is Philogen’s prorpietary product to treat skin…